GLP-1 drugs — which include Ozempic and its sister drug Wegovy, as well as Mounjaro and Zepbound — mimic at least one hormone produced by the gut to signal fullness, leading to a reduced appetite.

Starting in the new year, Independence Blue Cross, the region’s largest health insurer, will no longer cover anti-obesity drugs like Ozempic and Wegovy when they’re prescribed solely for weight loss.

People who use Ozempic or Wegovy for weight loss often find they must avoid certain foods to minimize side effects from the medications. Both drugs contain semaglutide, a synthetic version of a ...

Nestle is getting into the weight loss business. The world’s largest food and beverage company said it plans to launch a ...

Pennsylvania Medicaid insurers spent nearly $300 million on Wegovy, Zepbound, and other new anti-obesity drugs in the year that ended Oct. 31, according to a new analysis from Real Chemistry, a New ...

A prescription for Wegovy in the UK is roughly the same price as an expensive gym's membership fees - from around £160 a month. Famous users in the public eye such as Robbie Williams ...

Eli Lilly’s Zepbound bested Novo Nordisk’s Wegovy in the first head-to-head trial comparing weight loss outcomes for people with obesity or overweight, according to top-line results shared by Lilly ...

Novo Nordisk, the maker of perhaps the most sought-after prescription drugs in the world, says Ozempic and Wegovy are now being shipped regularly to wholesalers. After a year where products were ...

LONDON, Dec 13 (Reuters) - Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the U.S. drugmaker ...

However, this doesn’t mean every eligible adult can access semaglutide easily. An estimated 15 million Americans currently use GLP-1 medications such as Ozempic and Wegovy (brand names for semaglutide ...